Person-checked company records fromPerson-checked records $750See a worked exampleHuman review in progress

Talk to sales

KeptIndex

Companies

Vertex Pharmaceuticals

S&P 500Health CarePharmaceutical PreparationsNasdaq

Ticker VRTX. 102 dated commitments on record, 9 still open or being checked. History read from 2016, last updated 10 Oct 2026.

Execution profile

Commitments recorded
102
9 open
Clear outcomes
43
40 met · 2 late or partly · 1 not met or withdrawn
Delivered by the original date
93%
of 43 clear outcomes, all years on record
Commitments restated
9
4 pushed later, 343 days on average
Targets reduced
0
wording weakened: 0
No public record found
50
never counted for or against

Separate measures of what Vertex Pharmaceuticals said and what the public record showed, from 102 commitments. Every entry is listed below with its sources. How outcomes are decided

Kept Scores are not yet published

We are building the verified historical record first. Scores will be published once there is enough hand-checked history for them to mean something, and the methodology will be fixed and dated before the first score appears. This company has 7 commitments with a clear outcome in the last 3 years (the Kept Score window); the execution profile covers all years on record. How the score will work

Vertex Pharmaceuticals's complete recordEvery commitment, outcome and evidence link as a report and spreadsheet. Checked by a person, emailed within one business day · $49

Get the report · $49 Follow free by email

Coming due

Dated commitments Vertex Pharmaceuticals announced whose deadlines fall in the next six months. After each deadline, and a 30-day allowance, we check what the public record shows.

  1. 31 Dec 2026Submit global regulatory applications for zimislecel in type 1 diabetes
  2. 31 Dec 2026Share proof-of-concept results for VX-828 in people with cystic fibrosis
  3. 31 Dec 2026Complete full enrollment in the AMPLITUDE study of APOL1 inhibitors
  4. 31 Dec 2026Complete enrollment in the Phase 2 povetacicept study in generalized myasthenia gravis
  5. 31 Dec 2026Complete enrollment in both DPN Phase 3 studies of suzetrigine

Compared with its sector

93% of Vertex Pharmaceuticals's commitments with a clear outcome were delivered by the original date: in line with the Health Care median of 90%, across 11 S&P 500 Health Care companies with enough outcomes to compare (rank 3 of 11).

Median across the S&P 500: 78%. A count of outcomes, not a Kept Score or a rating. See every S&P 500 company

Commitment drift

Commitments restated
9
Deadlines pushed later
4
Average delay when pushed
343 days
Targets reduced
0
Wording weakened
0

Changes the company itself made to its own commitments, recorded as they happened. How drift is measured

Commitments

  • Deadline
  • Met
  • Late
  • Not met
  • Today

Get Vertex Pharmaceuticals's full record

Every commitment, outcome, evidence link and restatement as a report and spreadsheet, checked by a researcher against the SEC filings and emailed within one business day of payment.

Get the report · $49

Is this your company?

This page is public and free. Claim it to get a reminder before each deadline Vertex Pharmaceuticals announced, add your own sources to any entry, and receive a quarterly summary compared with your sector.

Claim this page

Does something on this page need correcting? Vertex Pharmaceuticals and any reader can ask us to check an entry, with a link to a public source.

Report an error Corrections policy

The Deadline Report

One email a week: the corporate commitments that came due, which were met, which slipped, and what is due next. Free. Stop any time.

No advertising. We never sell or share your address.